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Abstract
Hirschsprung disease (HSCR) is a rare congenital anomaly characterized by the absence of enteric ganglia in the distal
intestinal tract. While classified as a multigenic disorder, the altered function of the RET tyrosine kinase receptor is
responsible for the majority of the pathogenesis of HSCR. Recent evidence demonstrate a strong association between RET
and the homeostasis of immune system. Here, we utilize a unique cohort of fifty HSCR patients to fully characterize the
expression of RET receptor on both innate (monocytes and Natural Killer lymphocytes) and adaptive (B and T lymphocytes)
human peripheral blood mononuclear cells (PBMCs) and to explore the role of RET signaling in the immune system. We
show that the increased expression of RET receptor on immune cell subsets from HSCR individuals correlates with the
presence of loss-of-function RET mutations. Moreover, we demonstrate that the engagement of RET on PBMCs induces the
modulation of several inflammatory genes. In particular, RET stimulation with glial-cell line derived neurotrophic factor
family (GDNF) and glycosyl-phosphatidylinositol membrane anchored co-receptor a1 (GFRa1) trigger the up-modulation of
genes encoding either for chemokines (CCL20, CCL2, CCL3, CCL4, CCL7, CXCL1) and cytokines (IL-1b, IL-6 and IL-8) and the
down-regulation of chemokine/cytokine receptors (CCR2 and IL8-Ra). Although at different levels, the modulation of these
‘‘RET-dependent genes’’ occurs in both healthy donors and HSCR patients. We also describe another set of genes that,
independently from RET stimulation, are differently regulated in healthy donors versus HSCR patients. Among these ‘‘RET-
independent genes’’, there are CSF-1R, IL1-R1, IL1-R2 and TGFb-1, whose levels of transcripts were lower in HSCR patients
compared to healthy donors, thus suggesting aberrancies of inflammatory responses at mucosal level. Overall our results
demonstrate that immune system actively participates in the physiopathology of HSCR disease by modulating inflammatory
programs that are either dependent or independent from RET signaling.
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Introduction
Hirschsprung disease (HSCR) is a rare and congenital anomaly
of the enteric nervous system (ENS) that occurs with an average
incidence of 1 into 5000 live births. It is characterized by the
absence of enteric ganglia in variable lengths of distal intestinal
tract, resulting from the premature arrest of the craniocaudal
migration of vagal neural crest cells in the gut. HSCR has a
complex genetic inheritance, characterized by low and sex-
dependent penetrance with a strong male preponderance[1,2].
The major gene involved in HSCR pathogenesis is RET
(REarranged during Transfection), located on chromosome
10q11.2 and containing 21 exons, which codes for a tyrosine
kinase receptor[3,4]. Over one hundred RET mutations have
been described throughout the gene, including large deletions,
microdeletions, insertions, missense, nonsense and splicing muta-
tions[5,6,7]. Overall, these genetic anomalies lead to loss of
function of RET protein and/or to haploinsufficiency [8,9,10].
Although the majority of HSCR pedigrees show linkage with RET,
the coding sequence mutations of the RET gene could be only
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identified in up to 50% of familial cases and in 7–20% of sporadic
cases[11]. Therefore, non-coding mutations have been postulated
to play a role in unexplained cases[12]. A haplotype, including two
variants at25 and 21 bp from the RET transcription starting site
and a single nucleotide polymorphism (SNP) in exon 2 (c135G.A;
A45A), was first identified as associated with the HSCR
phenotype[13,14,15]. Furthermore, an intron 1 SNP (rs2435357
C.T) lying on the same haplotype was found to disrupt an
enhancer site[12,16] and to cause a reduced expression of the
gene[17,18]. Nevertheless, despite the fact that rs2435357 is
considered as the predisposing HSCR mutation, additional
functional data have shown a possible cooperative or synergistic
role for other intronic variants and/or promoter polymor-
phisms[14,19,20].
RET protein is expressed in neural crest-derived cell lineages
and is essential for their proliferation, migration and differentiation
during embryonic development of kidneys, peripheral nervous
system (sympathetic, parasympathetic and enteric) and for
spermatogenesis[21,22]. In this context, RET has been demon-
strated to play a central role in several intracellular signaling
pathways that regulate cellular survival, proliferation, differentia-
tion, migration and chemotaxis[23]. The activation of the RET
signaling cascade in physiological condition is secondary to the
stimulation of the receptor through a multi-protein complex that
involves both soluble ligands and cellular RET co-receptors.
Indeed, this process first requires the specific binding of one of the
four identified RET ligands [glial-cell line derived neurotrophic
factor family (GDNF), neurturin, artemin, persephin] with one of
the four glycosyl-phosphatidylinositol membrane anchored co-
receptors (GFRa1-4)[24]. As a second step, this binary complex
interacts with RET-receptor located in cell lipid rafts and the
binding triggers a RET autophosphorilation of specific tyrosine
residues[25]. Because of their pluripotent stem nature, neural crest
cells expressing RET receptor migrate towards developing
structures in the embryo to form tissues such as heart, bones
and cartilage of the craniofacial compartment, peripheral and
enteric neurons and glia and also skin’s pigment cells and smooth
muscle cells. Indeed, RET gene results expressed at variable levels
in most of these tissues[26,27,28,29].
RET transcripts have also been found in hematopoietic tissues
such as fetal liver, thymus, spleen and lymph nodes, thus
suggesting a role of RET in both the development and homeostasis
of immune system[29,30,31,32,33,34]. In this regard, it has been
shown in a RET-deficient mouse model that this tyrosine kinase is
a key regulator in the organogenesis of Peyer’s Patches[35] and
that RET receptor is also constitutively expressed on several
human primary immune cells[31,36]. Furthermore, RET/PTC1,
a rearranged RET tyrosine kinase gene playing a causative role in
the pathogenesis of papillary thyroid carcinoma, has been shown
to induce a vast pro-inflammatory program, thus demonstrating
that RET downstream signaling is directly associated with both
inflammation and malignancies[37]. However, those studies
examining the levels of RET receptor on human primary immune
cells gave incomplete or controversial results without disclosing the
definitive phenotypic distribution and levels of expression of this
tyrosine kinase on adaptive and innate primary immune cells.
Moreover, the functional correlates of RET receptor engagement
on immune cells have not yet been disclosed.
The present study takes advantage of a large cohort of HSCR
patients and control individuals to examine in detail the
phenotypic distribution and the levels of RET receptor expression
on primary immune cell subsets in correlation with RET
genotypes and mutations. Moreover, to functionally dissect the
physiology and physiopathology of this tyrosine kinase receptor in
triggering immune responses, we analyzed the effects of RET
engagement in modulating a large family of inflammatory/
regulatory genes in the peripheral blood mononuclear cells
(PBMCs) from both healthy donors and HSCR patients.
Results
Distribution and levels of expression of RET on immune
cells
The first characterization of RET distribution within immune
cell compartments performed in late 1990s did not detect any level
of RET transcripts or RET protein in primary lymphocytes,
differently from CD34pos progenitor cells, macrophages and
granulocytes that were found positive for RET expression[31].
This statement was implemented a few years later by another
report that demonstrated the presence of several RET isoforms in
monocytes, T (both CD4pos and CD8pos subsets) and in B
cells[36]. In particular, this study detected for the first time the
expression of RET receptor on the cell membrane of both
lymphocytes and monocytes through an indirect and single-color
flow cytometric approach. However, neither percentages of
expression nor mean fluorescence intensities (MFIs) exactly
quantified the levels of RET expressed on immune cell subsets.
To complete the phenotypic distribution of RET receptors on cells
from immune system, we extensively analyzed the expression of
this tyrosine kinase on human PBMCs of healthy donors through a
multicolor flow cytometric approach. Our results confirmed a
clear expression of RET receptor on both lymphocytes and
monocytes. Moreover, our data showed that, other than CD14pos
monocytes, CD3pos T and CD20pos B cells, also CD56pos Natural
Killer (NK) cells express remarkable levels of RET receptor
(Figure 1A). These results were also confirmed by experiments of
confocal microscopy (Figure S1). Indeed, the MFIs of RET on all
cell subsets were significantly higher when compared with
matched isotype controls (Figure 1B), and the overall expression
of RET receptor appeared to be different and highly variable
among the immune cell compartments analyzed.
To assess whether the levels of expression of RET on PBMCs
detected by the above-mentioned flow-cytometric approach were
reliable and could be used to exactly quantify the amount of
receptor presents on cells, we then proceeded to verify the
specificity and sensitivity of the anti-RET monoclonal antibody
(mAb) by analyzing the expression of RET receptor on several
cells lines known to express either high or low levels of this gene
(Figure 2A). As expected, we could detect very low levels of RET
receptor on IMR-32 and SK-N-MC cells, two neuroblastoma cell
lines shown to have small amount of RET transcripts[17,38]. In
contrast, we found that RET receptor was expressed at very high
levels on the membrane of MTC-TT cell line, which derives from
a medullary thyroid carcinoma (MTC) associated with multiple
endocrine neoplasia type 2A (MEN2A) and that produces high
levels of RET mRNA copies[39]. Finally, we detected substantial
levels of RET receptor on THP1 cell, a monocytic leukemia cell
line also known to produce remarkable amount of RET
transcript[31], although at intermediate level if compared with
our negative (IMR-32 and SK-N-MC cell lines) and positive
(MTC-TT cell line) controls. The different levels of RET receptor
expressed on the membrane of these cell lines showed a statistical
significant correlation with their relative copies of RET mRNA
transcript (Figure 2B), thus demonstrating that the levels of
expression of RET receptor exactly matched with the amount of
RET mRNA transcribed within the same cell lines. All together,
these results confirm that our flow cytometric approach is a
RET on Immune Cells from Hirschsprung Patients
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reliable methodology to detect the presence and levels of
expression of RET receptor on cell membrane.
Expression of RET on immune cells from HSCR patients
and associations with RET genotypes
Since loss-of-function RET mutations are pathogenic allele
variants leading to the onset of HSCR, we analyzed the expression
of RET receptor on immune cell subsets from a cohort of 50
HSCR patients. As observed for healthy donors, we found that the
overall amounts of RET receptor on lymphocytes and monocytes
from HSCR patients were comprised in a large range of
expression, thus demonstrating a large degree of inter-individual
variations (Figure 3A). Moreover, we did not detect any specific
phenotypic distribution of RET receptor (neither increased nor
decreased expression) among the several subsets of primary
immune cells analyzed (data not shown).
We next determined if the expression of RET receptor on
immune cells from HSCR donors correlates with specific
genotypes at the RET locus. In particular, we focused on four
single nucleotide polymorphisms (SNPs) of the coding region
located at exons 2 (rs1800858), 11 (rs1799939), 13 (rs1800861) and
14 (rs1800862), that are known to have different frequencies in
HSCR patients versus normal controls[40]. Exon 2 SNP
represents a tag marker for the HSCR predisposing haplotype[16]
and it has been shown to be associated with a reduced gene
expression[17]. Therefore, a distorted distribution of the two
alleles of the exon 2 SNP would theoretically explain the variability
of RET receptor expression on PBMCs from HSCR patients. To
test this hypothesis, the cohort of HSCR subjects was subdivided
into the three subgroups having different genotypes at RET exon 2
SNP locus, namely GG (present on 15 HSCR patients), GA
(present on 20 HSCR patients) and AA (present on 15 HSCR
patients), with GG and AA being the wild type and homozygote
variants, respectively. Our analyses did not reveal any significant
difference of RET receptor expression between the three
subgroups of lymphocytes and monocytes from HSCR patients
showing different RET genotypes at this locus (Figure 3B). Even
when lymphocyte subsets (B, T and NK cells) were separately
analyzed, we did not observe any differential effects of the RET
genotype at the exon 2 SNP locus on the expression of RET
receptor (Figure S2). These data demonstrate that neither the
presence nor the absence of the HSCR predisposing haplotype
affects the phenotypic distribution of RET on circulating immune
cells. Finally, we also evaluated the presence of a possible
association between the levels of the RET receptor and the
genotypes at the three other SNPs analyzed, namely those of exons
Figure 1. Phenotypic distribution and levels of expression of RET receptor on circulating immune cell subsets. (A) Flow cytometric dot
plot (upper line) and histogram (lower line) graphs showing a representative example from an healthy donor of CD14pos monocytes, CD56pos (NK
cells), CD3pos (T cells) and CD20pos (B cells) lymphocytes expressing RET receptor (black line) compared to isotype control (gray shaded histograms).
(B) Summary graph of dot plots with medians (horizontal black bars) showing the mean fluorescence intensities (MFIs) of RET receptor on immune
cells (black symbols) compared to that of isotype controls (open white symbols) from 17 healthy donors.
doi:10.1371/journal.pone.0059066.g001
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11, 13 and 14. Similar to the results obtained for exon 2 SNP locus
of RET gene, no significant associations were observed between
these latest genotypes and the expression of RET on immune cells
from HSCR patients (Figure S3).
After having excluded any possible role of RET genotypes in
modulating the expression of RET receptor on immune cells, we
evaluated whether RET gene mutations in cells from HSCR
patients affected the expression of RET receptor. Mutational
analysis of RET gene within the cohort of 50 HSCR donors
identified 9 distinct RET sequence variations. We then proceeded
to distinguish between potentially causative mutations and neutral
variants of RET. To this end, the impact of these variations on
protein structure and function for non-synonymous changes and
on splicing for intronic or synonymous variants was evaluated
using Polyphen, SIFT and Panther softwares (Table
S1)[41,42,43,44,45,46]. Data already published on functional
assays of RET mutations were also used to recognize putative
severe nucleotide changes[47]. Five of the nine variants demon-
strated a significant ‘‘pathogenic’’ status, while the impact of other
4 gene variants on RET function was uncertain. Among these
latter four mutations, there are the intronic variants
c.1063+9G.A and c.1880-16C.T, the sequence c.2944C.T
(p.R982C) whose role in determining HSCR had already been
excluded by functional tests[8] and the c.2556C.G (p.I852M)
variation which has been considered as a tolerable mutation by all
the algorithms. These four non-pathogenic mutations were no
longer considered for our analyses. We then assessed whether the
amounts of RET receptor on immune cells was affected by the
presence of the 5 pathogenic mutations. Our data show that the
levels of RET receptor expression were significantly higher on all
lymphocyte subsets (B, T and NK cells) of HSCR patients carrying
a putative pathogenic variant of RET gene compared to those of
HSCR patients not carrying any mutation in RET gene. Although
not statistic significant, we observed a similar trend also within the
monocyte compartment (Figure 4).
Similar to what we found by comparing immune cells from
HSCR individuals with and without mutations of RET gene, we
detected a statistically significant higher expression of RET
receptors in PBMCs from HSCR patients with loss-of-function
RET pathogenic variant compared to that of HSCR individuals
carrying a non-pathogenic mutation of the same gene. Indeed, the
levels of RET receptor on PBMCs from this latter cohort of
patients were similar to that of HSCR patients without any known
RET gene mutation (Figure S4). This finding implies that only the
Figure 2. Correlation between the RET receptor expression and RET transcripts on four different cell lines. (A) Flow cytometric
histogram graphs showing the MFI levels of expression of RET receptor (black line) of 4 different cell lines. Gray shaded histograms represent the
isotype controls. (B) Histogram bar graph showing the number of RET mRNA copies produced by the same cell lines displayed in panel A and
analyzed within the same time-frame in culture. Values are normalized on SK-N-MC cell line of one experiment and are reported as fold increased in
expression (22DCt) as mean of three independent experiments. Of note, the level of RET receptor expressed on cell membrane significantly correlated
with the amount of RET transcripts, as assessed by the Spearman rank test for correlation.
doi:10.1371/journal.pone.0059066.g002
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Figure 3. Expression of RET receptor on immune cells from HSCR patients associated with a single nucleotide polymorphism at
exon 2. Summary graph of statistical dot plots showing MFI values of RET receptor expressed on lymphocytes and monocytes from 50 HSCR patients
with medians (horizontal black bars) either in the absence (A) or in the presence (B) of an association analysis stratification based on the genotype at
the exon 2 of RET gene (SNP rs1800858). We did not detect any statistically significant association between the phenotypic distribution of RET
receptor on immune cells with RET genotype at exon 2 SNP.
doi:10.1371/journal.pone.0059066.g003
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putative pathogenic RET gene variants are associated with the
increased expression of RET receptor on immune cells.
RET dependent and independent pro-inflammatory
programs in immune cells from HSCR patients and
healthy donors
Although it has been demonstrated that the activation of RET
signaling pathway induces the expression of a large set of pro-
inflammatory genes in primary thyrocytes[37] and that RET is
actively involved in immune system homeostasis[35], very little is
known on the physiologic role of RET receptor expressed on
circulating immune cells. Our hypothesis is that the engagement of
RET receptor expressed on primary immune cells is somewhat
involved in the homeostasis of immune responses and that the
stimulation of this tyrosine kinase on PBMCs from HSCR patients
might be possibly associated with some severe and inflammatory
clinical outcomes, such as Hirschsprung’s associated enterocolitis
(HAEC). To test this idea, we customized a TLDA ‘‘inflamma-
tory’’ card containing the primers and probes of 96 genes that
included all main cytokines, chemokines, receptors and immune
mediators normally involved during acute and chronic phases of
inflammation (Table S2).
In order to trigger the RET pathway on PBMCs, we incubated
RETpos PBMCs with GDNF ligand (100 ng/ml) and the GFRa1
co-receptor (1 mg/ml) for 5 hours on the basis of both our
experience and previous published reports[36,48]. Through this
experimental setting we were able to examine the effects of RET
engagement in modulating the transcript levels of all 96
Figure 4. Expression of RET receptor on immune cells from HSCR patients associated with pathogenic mutations of RET gene.
Summary graph of statistical histogram bars (upper panel) and dot plots (lower panel) showing MFI values of RET expressed on monocytes, T, B and
NK lymphocytes from 46 HSCR patients stratified on the basis of individuals either carrying (gray histogram bars in upper panel and black symbols in
the lower panel) or not carrying (empty histogram bars in upper panel and empty symbols in the lower panel) pathogenic RET mutation. 4 HSCR
patients were excluded from the analysis because they were carrying mutations of the RET gene with uncertain effects.
doi:10.1371/journal.pone.0059066.g004
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customized genes comprised within ‘‘inflammatory’’ TLDA card,
which also included 5 reference genes (GAPDH, actin, 18s
ribosomal RNA, b2-microglobulin and HPRT1) (Table S2). The
evaluation of the transcript levels in PBMCs from healthy donors
and HSCR patients, either in the presence or in the absence of
treatment with GDNF and GFRa1, revealed that 78 out of 96
genes were expressed (Table S3). We next proceeded to analyze
the statistics of those 69 genes for which there were no more than
two data missing in one of the four groups (treated and untreated
PBMCs, healthy donors and HSCR patients) or one data missing
in more than one group.
Our analyses identified two main clusters of genes exhibiting
different modulatory patterns (Table S3). The first group includes
13 genes that displayed differences in their transcript levels
following RET stimulation. The altered expression of genes in this
group appear to be ‘‘RET-dependent’’, as the engagement of RET
with GDNF and GFRa1 induced a significant modulation of these
genes in both healthy donors and HSCR patients. Among this
group 1, there are different chemokines (CCL2, CCL3, CCL4,
CCL7, CCL20, CXCL1), cytokines (IL-1b, IL-6 and IL-8), one
chemokine receptor (CCR2), one cytokine receptor (IL8-Ra), the
tumor necrosis factor (TNF) and the prostaglandin-endoperoxide
synthase 2 (PTGS2). Among all these 13 RET-dependent genes,
CCR2 and IL8-Ra resulted to be down-modulated in healthy
donors and HSCR patients, while all other genes were found to be
up-regulated in both cohorts. We then proceeded to analyze
whether the activation of RET signaling pathway with its ligand
and co-receptor induced a different regulation of these genes in
healthy donors compared to HSCR patients. Although the
differences did not reach a statistical significance, the transcripts
of the majority of the13 RET-dependent genes were expressed at
higher levels in PBMCs from HSCR patients compared to healthy
donors, with the only exception of CCL2 and CCL7. Even the fold
decrease of CCR2 and IL8-Ra was lower in PBMCs from HSCR
patients compared to that of healthy donors (Figure 5).
In order to confirm the results obtained with the TLDA
‘‘inflammatory’’ customized card, we enlarged our cohorts by
enrolling 3 additional healthy donors and 3 HSCR patients and
we proceeded to validate the modulation of the 13 RET-
dependent genes by incubating PBMCs with GDNF and GFRa1
co-receptor and by performing an alternative real time PCR-based
experimental approach. The results showed a very similar pattern
of regulation and a similar heterogeneity in both the 3 additional
healthy donors and 3 HSCR patients. Indeed, our analysis
confirmed that 12 out of the 13 RET-dependent genes responded
to the treatment by changing their expression in the same
direction indicated by the TLDA array, with the only exception of
the TNF gene. In particular, 10 genes were up-regulated upon
RET activation, while CCR2 and IL8 Ra were down-regulated
(Table S4). Although only the CCL20 and PTGS2 genes showed a
statistically different expression between treated and untreated
cells, the general trend of the13 RET-dependent gene expression
was maintained before and after the treatment, similar to what we
observed with TLDA array (p = 0.0001 at the binomial test).
In order to further strengthen our results, we also tested whether
the up-regulation of several genes following the engagement or
RET was associated with an increased secretion in cell superna-
tants of the related soluble and inflammatory cytokines and
chemokines. Regardless of the treatment of PBMCs with RET
ligand and co-receptor, we could not detect any levels of IL-8,
CCL4, TNF and CCL7, in line with the fact that their related
genes were the ones showing the lowest fold increases among
the13 RET-dependent genes. In contrast, we found that the
engagement of RET receptor with its ligand and co-receptor
resulted in an increased production of all other measured cytokines
and chemokines. We also found that the heterogeneous up-
modulations of the RET dependent genes was also mirrored by a
similar heterogeneity in the levels of the relative cytokines and
chemokines secreted in cell supernatants by PBMCs. Even the
different degrees of positive regulation of CCL20, IL1-b, CCL2,
CCL3, IL-6, CXCL1 between healthy donors and HSCR patients
paralleled the amounts of related soluble molecules present in cell
culture. Indeed, taking CCL3 and CXCL1 as representative
examples, we could not detect any production of these two
chemokines from PBMCs of healthy donors in line with low levels
of up-modulation of their related genes in this cohort. On the
other side, the engagement of RET induced a higher secretion of
detectable amounts of CCL3 and CXCL1 in HSCR patients, in
line with higher levels of positive regulation of their related genes
(Table 1).
The second cluster is composed of genes that are differently
expressed in healthy donors compared to HSCR patients and it
can be classified as either ‘‘RET-independent’’ or ‘‘HSCR
associated’’, since the modulation of transcripts levels was not
associated with RET engagement but seemed to be intrinsic to the
HSCR itself. This second group includes genes encoding for the
colony stimulating factor 1 receptor (CSF-1R), two members of the
family of the interleukin 1 receptor (IL1-R1 and IL1-R2),
transforming growth factor beta 1 (TGFb-1), interleukin 18 and
19 (IL18 and IL19) and the secreted phosphoprotein 1 (SPP1). In
particular, our analyses showed that modulation of CSF-1R, IL1-
R1, IL1-R2, TGFb-1 and IL-18 genes were significantly higher in
both freshly purified and treated (with GDNF and GFRa1)
PBMCs from healthy donors compared to that HSCR patients. In
contrast, the mRNA transcripts of IL-19 and SPP1 resulted higher
in HSCR patient compared to healthy donors (Figure 6).
We also identified a third set of genes (Group 3 in Table S3)
whose levels of mRNA transcripts were differently regulated within
each donor in both cohorts of healthy controls and HSCR patients
regardless of treatment of PBMCs with GDNF and GFRa1. Due
to the heterogeneous expression of genes included in this Group 3,
it was not possible to perform statistic analyses and draw definite
clear conclusions. Finally, a last set of genes whose changes are not
statistically significant was also identified and no longer considered
[labeled as not significant (n.s.) in Table S3].
Discussion
The RET gene is an established key factor needed for the
development of both the enteric nervous and the escretory
system[49,50] and its loss of function mutations leads to the onset
of HSCR[5,6,7]. Recently, it has been demonstrated that RET is
expressed on primary immune cells and also plays a major role in
the regulation of both immune system homeostasis and inflam-
mation[35,36,37]. In the present study, we took advantage of a
unique cohort of HSCR and healthy donors to fully explore the
cellular distribution and the levels of RET receptor on human
PBMCs. In particular, we characterized and quantified the levels
of expression of RET receptor on human monocytes, B, T, and
NK cells. To this end, we first correlated the amounts of RET
transcripts with the relative levels of RET protein expressed on
several cell lines known to transcribe either high or low copies of
RET mRNA (i.e. IMR-32, SK-N-MC, MTC-TT and THP1 cell
lines) [17,31,38,39]. Our results show a significant correlation
between the two above-mentioned parameters, thus clearly
demonstrating that our multicolor flow-cytometry experimental
approach is a reliable methodology to exactly quantify the MFI of
RET on Immune Cells from Hirschsprung Patients
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RET expression on cell membrane and can be also an useful tool
for others in the field.
We then evaluated the levels of RET receptor on a large cohort
of HSCR patients and we found an heterogeneous level of
expression of RET protein within all four compartment of innate
(monocytes and NK cells) and adaptive (T and B lymphocytes)
immune cells analyzed. To better understand this phenomenon,
we stratified the patients on the basis of both their RET genotypes
and mutations, given the fact that specific RET haplotypes, such
as the one containing the SNP2 variant allele, are associated with
reduced RET expression[16]. Our results excluded any possible
role of the exon 2 marker in determining the levels of RET
receptor, thus not confirming that the reduced RET mRNA
transcript are associated with the predisposing haplotype, as
previously reported[17,18]. This discrepancy might be explained
by postulating differences in the tissue specific pattern of RET
expression or between the mRNA and protein expression levels.
As an example, these haplotypes may exert effects on the neural
crest and kidney developmental defects but may not have effects
on RET receptor levels and functions in the immune system
components. We had similar negative data also for the other three
additional RET coding SNPs in exons 11, 13 and 14.
Genomic analysis of the RET locus was also used to determine
which HSCR patients had deleterious mutations that may
influence the expression of RET receptor on immune cells. Nine
out of fifty patients carried potentially pathogenic RET mutations
and the effect of these variants was predicted by means of several
different software (Table S1). Only 5 out of 9 mutations were
pathogenic while the remaining 4 variants were not further
considered due to the lack of clear evidence about their pathogenic
effect. We then associated the five remaining pathogenic
mutations, predicted to have severe effects on the functional
outcome of RET protein, with the levels of RET receptor on
primary immune cells. Surprisingly, we found that T, B and NK
cells from HSCR patients carrying the RET loss-of-function
mutations express significantly higher amounts of RET receptor
compared to those of HSCR individuals not carrying pathogenic
RET variants. Monocytes showed a similar trend, although it did
not reach a statistical significance. In this regard, we have to take
into account that only 20% or less of sporadic HSCR patients
carry loss-of-function RET variants[12,40], thus explaining why
we could find only 5 of these patients in our large cohorts of 50
HSCR individuals. We are currently recruiting others HSCR
subjects carrying pathogenic RET variants in order to increase the
power of our statistics also within the monocyte compartment.
This unexpected higher expression of RET receptors on lympho-
cytes from HSCR patients carrying severe RET mutations might
be explained by two different cellular mechanisms: 1) a
transcriptional feed-back assuring proper levels of the RET
protein in the presence of low RET activity through a
compensatory mechanism already described also for other mutant
disease genes [51,52] and 2) an intracellular accumulation of
mutant RET receptor due to protein misfolding, as already
reported for other defective cell membrane receptors leading to
Figure 5. Modulation of RET-dependent genes. Colorimetric scale graph showing the fold increase (red) and decrease (green) of mRNA
transcripts for those genes modulated in both PBMCs from healthy donors and HSCR patients following treatment with GDNF and GFRa1. The
differences in fold changes of RET-dependent genes between the PBMCs of three healthy donors and three HSCR patients analyzed are indicated by
means of 22DDCt values included in each square and by the ranges of color tonality of the same square.
doi:10.1371/journal.pone.0059066.g005
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impairment of the cell response mechanisms [i.e. the ubiquitin-
proteasome system (UPS) or autophagy] and inducing the onset of
human disease[53,54]. Further analysis will be needed to confirm
such an observation, and eventually to test these two hypotheses.
Another aim of the present work was to assess whether the
presence of RET receptors on primary immune cells is
functionally relevant in activating inflammatory process, as
demonstrated for primary thyrocytes[37]. To this end, we
customized a 96 real-time PCR array, namely an Array Card
with inventoried TaqManH Gene Expression Assays, in which the
inflammation pathways tested are represented by all main
cytokines and chemokines together with their related receptors,
and by other immune mediators normally involved in the
inflammatory processes. Through this customized ‘‘inflammatory
card’’, we sought to investigate the expression patterns of specific
target genes both in physiological and pathological conditions by
assaying cells from controls and HSCR patients. In fact, before
RNA extraction, cells were treated with the GDNF and GFRa1,
whose expression in human PBMCs had previously been excluded
by RT-PCR (data not shown). The use of GDNF and GFRa1 to
trigger RET downstream pathways is in accordance with other
previously published reports [36,48] and also relies on the fact that
GDNF is the strongest activator of RET signaling in enteric glial
cells upon a number of physiological and pathological events[55].
Moreover, immune cells are expected to respond to RET ligands
as they express the RET receptor, and GDNF and GFRa1 are
known to be highly expressed in intestine during development[56].
These experimental evidence prompted us to hypothesize that
during the course of intestinal inflammation in fetal or neonatal
life, a clinical outcome often occurring in Hirschsprung patients
and known as HAEC, RETpos circulating immune cells from the
periphery might interact with RET ligands present at the mucosal
level. As a result of these possible interactions, immune cells could
release pro-inflammatory mediators and actively contribute to
intestinal inflammation.
The first group of genes clustered by our statistic analyses
included molecules whose transcripts were modulated only
following treatment of PBMCs with GDNF and GFRa1. We
defined this cluster of genes as ‘‘RET-dependent’’. Many of these
genes encoded for chemokines or chemokine receptors, thus
indicating that the engagement of RET might regulate the
trafficking and the migration of immune cells upon inflammatory
stimuli. Among these molecules, we found of particular interest the
up-regulation of CCL20, an important mucosa-associated che-
mokine expressed in the intestinal epithelium and required for the
recruitment of immune cells necessary for maintaining intestinal
homeostasis[57,58]. Indeed, CCL20, also known as or Macro-
phage Inflammatory Protein-3 (MIP3A) is a small cytokine
strongly chemotactic for lymphocytes and dendritic cells in
inflamed site upon binding on target cells the chemokine receptor
6 (CCR6)[59]. Therefore, it is likely that the engagement of RET
at the mucosal sites (i.e. intestinal mucosa) is able to activate the
CCL20-CCR6 pathway and, therefore, participate in modulating
the homeostasis of the gut associated lymphoid tissue (GALT) in
response to infections. Noteworthy, the expression of CCL20 has
been found significantly up-regulated in PBMCs of patients with
ulcerative colitis and Chron’s Disease[60,61,62], being the role of
CCL20 to link innate and adaptive immunity by attracting
immature dendritic cells, effector memory T cells and B cells[59].
Moreover, CCL20 is also involved in activating the pro-
inflammatory program in thyrocytes derived from the papillary
thyroid carcinoma (PTC) where the fusion protein, termed the
RET/PTC1 oncogene, displays ligand-independent autophospho-T
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rylation and has been shown to activate a set of genes in vitro and in
vivo[37].
Within this first group of RET-dependent genes, we observed
increased levels of CCL2 and IL-8 mRNA, along with the
subsequent decreased amount of their receptor transcripts, CCR2
and IL-8Ra. Our data are in line with the experimental evidence
showing that the binding of cytokines or chemokines to their
putative membrane receptors trigger the internalization and
degradation of the corresponding receptor, a phenomenon that
has already been described for CCR2 and IL-8Ra [63,64]. This
could be a possible compensatory mechanism for regulating the
RET-mediated lymphocyte trafficking to the inflammation site in
GALT. Again, CCL2 and IL-8 are two important mediators on
inflammation. Indeed, Chemokine (C–C motif) ligand 2 (CCL2),
also known as monocyte chemotactic protein-1 (MCP-1), recruits
monocytes, dendridic and T cells to sites of tissue injury[65], while
IL-8 is a chemokine produced mainly by macrophages that mainly
induces the chemotaxis of neutrophil granulocytes (IL-8 is also
known as neutrophil chemotactic factor)[66].
Although not statistically significant, we observed that the
degree of transcripts levels of the 13 RET dependent genes was
generally higher in HSCR patients compared to healthy donors.
Even the down-regulation of CCR2 and IL8-Ra was less
pronounced in HSCR subjects compared to normal controls.
This phenomenon suggests that the engagement of RET might
induce a greater inflammatory responses in HSCR patients, in line
with some clinical outcomes of the disease. The lack of statistic
significance might be explained not only by the limited size of the
sample, but also by the fact that none of the 6 HSCR patients
analyzed was carrying a loss-of-function RET mutations (data not
shown). We hypothesize that the stimulation of PBMCs from
HSCR patients having pathogenic RET variants and whose
lymphocytes express higher amounts of RET receptor might
induce a more robust, and likely statistically significant, modula-
tion of the 13 RET-dependent inflammatory genes compared to
that observed in immune cells from healthy donors. We are
currently enrolling through our clinical facility a larger numbers of
patients affected by this rare diseases and carrying loss of functions
RET mutations to validate out hypothesis. However, our data
clearly show that the pattern of RET-dependent regulation of
inflammatory genes is conserved in both healthy donors and
HSCR patients. Therefore, it is conceivable that the stimulation of
this tyrosine kinase in those#20% of HSCR patients carrying a
pathogenic RET mutation and an increased expression of RET
receptor could lead to the onset of severe and aberrant
inflammatory outcomes.
Figure 6. Modulation of RET-independent genes. Histogram bar graph showing the relative transcript levels of genes that, regardless of
treatment with GDNF and GFRa1, are differently modulated in PBMCs from healthy donors and HSCR patients. The amounts of mRNA either in freshly
purified (left part of the graph) or treated (right part of the graph) of PBMCs of healthy donors (white bars) and HSCR patients (black bars) were
detected by Taqman Low Density Array (TLDA) card.
doi:10.1371/journal.pone.0059066.g006
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The second group of inflammatory genes (CSF-1R, IL1-R1,
IL1-R2, TGF-b1, IL-18, IL-19, SPP1) was defined as ‘‘RET-
independent’’, because they were differentially expressed in
PBMCs from HSCR patients and healthy donors regardless the
stimulation of RET with its ligand and co-receptor. For this reason
we also define them as ‘‘HSCR associated’’ genes. Among these
genes, the ones that showed the most remarkable and statistically
significant decreased levels of mRNA transcripts in HSCR patients
compared to those of healthy donors were i) CSF-1R, also known
as macrophage colony-stimulating factor receptor (M-CSFR or
CD115) that controls the differentiation and function of macro-
phages[67], ii) IL1-R1 and IL1R2 that are involved in many
cytokine-induced immune and inflammatory responses[68] and iii)
TGF-b1 that belongs to TGF-b superfamily of cytokines and
controls cell growth, proliferation and differentiation[69]. Since all
these 4 genes are strongly involved also in regulating inflammatory
processes also at mucosal levels, it is possible that the differences
between HSCR patients and healthy donors in their transcript
levels might represent the ground accounting for an immunolog-
ical impairment predisposing to the onset of a life-threatening
clinical outcomes occurring in HSCR patients. Indeed, HAEC,
occurring in 5–30% of patients, is the most severe complication of
HSCR and is characterized by explosive diarrhea, abdominal
distension, fever and impending septic shock[70]. Although
involvement of genetic and environmental factors, including local
defense mechanisms and immune system dysfunction has been
proposed, HAEC etiology remains mostly undisclosed[71,72]. In
this context, the down-regulation of pro-inflammatory genes, such
as CSF-1R, IL1-R1, IL1-R2 and TGF-b1, in human primary
immune cells could play an important role in the physiopathology
of HAEC. As a matter of fact, studies performed in IL1-R1 knock-
out mice provide evidence that the lack of IL1 receptor signaling
pathway is associated with both an increased susceptibility to
listeria monocytogenes and leishmania infections and with an
attenuated delayed-type hypersensitivity responses[73]. Moreover,
since macrophages are central effectors of innate immune
responses for the recognition and clearance of pathogens[74],
impairments in the CSF-1R transcription might be associated
and/or contribute to the onset of HAEC. In addition, defects in
TGF-b1, an important regulator of myeloid cell homeostasis[75],
could potentially be linked to the onset of HAEC. Overall, a
decreased expression of genes encoding for these important
inflammatory mediators might be highly relevant to explain those
clinical outcomes of HSCR diseases associated with dysfunctions
of immune system.
Our experimental results also highlight that the vast majority of
both RET-independent and RET-dependent genes are associated
with the homeostasis and the functions of monocytes/macrophag-
es (such as IL-1 associated genes, CSF-1R, CCL2, CCR2, CCL3,
CCL4, CCL7, CCL20, CXCL1, CSF-1R, IL-6), neutrophils (such
asIL-8, IL8-Ra, CXCL1), dendritic (such as CCL2, CCR2,
CCL20) and NK (such as CCL4) cells. This suggests that the
innate cellular arm of immune system play a major role in both the
RET-mediated regulation of the immune system homeostasis and
in the physiopathology of HSCR disease. Further studies are
needed to specifically address the mechanisms and the effect of
RET-induced activation of the several subsets of innate immune
cells to possibly disclose their pathogenic role during the course of
HSCR.
In summary, the present study links several genetic features of
HSCR with its immunological counterparts by first showing that
the increased expression of RET receptors on human PBMCs
from HSCR patient correlates with the presence of loss of function
RET mutations. Moreover, we demonstrate that the engagement
of RET on primary immune cells induces the modulation of
several genes involved in the inflammation processes. Remarkably,
the regulation of these RET-dependent genes is present in both
healthy donors and HSCR patients, although at different levels.
Finally, our results identify another small set of RET-independent
genes that, regardless of stimulation of RET with its ligand and co-
receptor, are differently regulated in healthy donors versus HSCR
patients. All together our experimental evidence show that the
involvement of the immune system in the physiopathology of
HSCR can be either RET dependent or independent.
Materials and Methods
Study Subjects
A cohort of 50 sporadic HSCR patients, 16 females and 34
males, recruited through regular hospital admission within the
Department of Pediatric Surgery of Giannina Gaslini Institute
(IGG), an Italian referential centre for HSCR disease, was studied.
The diagnosis of HSCR was performed following all clinical and
laboratory criteria, as recently revised by our group[76]. In
particular, the examination of biological specimens of adequate
rectal suction biopsies by the department of pathology included
the Acetylcholinesterase (AChE), Lactate Dehidrogenase (LDH)
and NADPH-diaphorase histochemical staining. In case of
admitted patients that had already performed surgical procedures
elsewhere, a comprehensive re-evaluation of gut specimen was
repeated to avoid inclusion of non-HSCR patients. PBMCs were
obtained from blood draws in accordance with the clinical
protocol approved by the Institutional Review Board (IRB) of
IGG. Parents of patients under 18 years old signed a consent form
that was approved by the above mentioned IRBs in accordance
with Italian laws and with Declaration of Helsinki. PBMCs from
healthy volunteers were obtained from buffy coat of healthy
donors that signed consent forms in accordance with clinical
protocols approved by the IRB of Desio Hospital, Milan, Italy.
PBMCs were obtained by Ficoll-Hypaque (GE Healthcare)
density gradient centrifugation from whole blood or buffy
coats[77].
Flow cytometry and confocal microscopy
For multicolour (up to 6 colours) (FACS Canto II, BD
Pharmigen)[77], flow cytometric analyses PBMCs were stained
with PerCP-Cy5-labeled CD14, pacific blue-labeled CD20
(Biolegend), allophycocyanin-labeled CD56 and fluorescein iso-
thiocyanate-labeled CD3 (BD Pharmigen) monoclonal antibodies
(mAbs). Viable cells were detected through the aqua live/dead
staining (Invitrogen). For intracellular staining of RET, after an
incubation of 30 minutes at 4uC with the above mentioned anti-
CD56, -CD3, -CD20 and -CD14 mAbs, PBMCs were washed,
fixed and permeabilized with cytofix/cytoperm following manu-
facturer’s instructions (BD Pharmigen) and incubated separately
for 30 minutes at 4uC with the phycoerythrin- labeled anti RET
mAb (R&D System). To saturate and block FccIII receptors on
monocytes and avoid false positive, PBMCs were pre-incubated
with human IgGs antibodies (Sigma-Aldrich) at 4uC for 20
minutes. Data were analyzed using FlowJo software (TreeStar) and
the expression of RET receptor on immune cell subsets was
measured by detecting the level of its mean fluorescence intensity
(MFI).
For confocal microscopy, PBMCs were seeded on glass slides
pre-treated with poly-L-lysine. After 30 minutes at 37uC, cells were
washed in PBS added with 2% FBS (South American Origin;
Lonza). Cells were fixed with paraformaldehyde (PFA) 4% in PBS
for 15 minutes at room temperature (RT) on dark and washed
RET on Immune Cells from Hirschsprung Patients
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with washing buffer [0,05% Tween 20 (Merckel) in PBS]. After
blocking with 2% bovine serum albumin (BSA) for 30 minutes at
RT, cells were stained with un-coniugated anti-RET pAb (Santa-
Cruz) and anti-CD56 (MBL), or anti-CD19 (Dako) or anti-CD3
(Dako) Abs for one hour at RT. Before CD3 staining, cells were
permeabilized with 0,3% Triton-X in PBS/2% FBS and
incubated with blocking solution PBS/2%BSA in 5% donkey
serum for one hour at RT. Cells were then washed and incubated
with the secondary antibodies for 30 minutes at RT: Alexa FluorH
488 Donkey anti-Rabbit, Alexa FluorH 647 Donkey anti-Goat,
Alexa FluorH 488 Donkey anti-Goat and Alexa FluorH 555
Donkey anti-Mouse (Invitrogen) were used. After washing, cells
were stained with DAPI (Molecular Probes) for one minute on the
dark to detect cell nucleus. Glasses were mounted with Fluor
PreserveTM Reagent (Calbiochem) and cells were analyzed with a
laser scanning confocal microscope (FluoView FV1000; Olympus).
Images were acquired with an oil immersion objective (4061.3 NA
Plan-Apochromat; Olympus). For image analysis, Imaris X64
6.2.1 software (Bitplane, AG) was used.
Culture of human cell lines
Neuroblastoma cell lines SK-N-MC and IMR-32 were cultured
in Minimum Essential Medium Eagle MEM medium (SIGMA),
monocytic leukemia cell line THP1 was grown in RPMI-1640
medium (Euroclone) and medullary thyroid carcinoma cell line
MTC-TT was maintained in culture in F-12 Ham’s medium
(Euroclone). All medium were supplemented with 10% fetal
bovine serum (FBS, New Zealand), 1% L-glutamine (100X),
100 U\ml penicillin and 100 mg\ml streptomycin and cell
cultures were maintained at 37uC with 5% CO2 in a humidified
incubator. Around 5X10E6 cells were collected from cell cultures:
3610E6 cells were washed in DPBS and used for RNA extraction,
2610E6 cells were used for cytofluorimetric experiments. All the
above-mentioned cell lines have been purchased from ATCC,
USA.
RNA isolation and reverse transcription
Total RNA from cells was isolated by a commercial RNA
purification kit (RNeasy Mini kit, Qiagen, GmbH, Germany)
according to the manufacturer’s protocol. 1 mg of total RNA was
reverse transcribed by iScript cDNA synthesis kit (Bio-Rad
Laboratories) according to the manufacturer’s protocol. Real time
quantitative PCR was performed using inventoried Assays-on-
DemandTM provided by Applied Biosystems (Table 2). PCR
reactions were performed using the iQTM5 Real Time PCR (Bio-
Rad Laboratories). The expression of mRNA in cell lines was
evaluated using the comparative Ct method (DDCt) and the
normalization was achieved by the mean values of reference genes.
Real Time PCR amplification was performed in triplicate and
repeated twice.
Mutation Analysis
Genomic DNA was extracted from peripheral blood mononu-
clear cells (PBMCs) by a standard technique. DNA samples from
HSCR patients were subjected to mutation screening of the
twenty-one exons, and relative intron-exon boundaries of the RET
gene by mean of direct sequencing of the corresponding
amplification products. PCR products were purified by ExoSAP-
IT (GE Healthcare) and directly sequenced using Big Dye v1.1
and a ABI3130 automated sequencer (Applied Biosystems, Foster
City, CA, USA).
Customized gene array analysis
107 freshly purified PBMCs from three healthy donors and
three HSCR patients without mutations of the RET coding
sequence, were collected and resuspended in RPMI-1640.
Samples were stimulated with human GDNF and human GFRa1
at the final concentration of 100ng/ml and 1 mg/ml respectively
(R&D Systems) and incubated at 37uC in 5% CO2. After five
hours incubation, cells were pelletted, RNA was extracted from
cells and reverse transcribed as described above. For these
samples, the detection of 96 genes was performed using custom
Taqman Low Density Array (TLDA) cards (Applied Biosystem) on
a 7900HT fast RT-PCR using SDS 2.2 software according to the
manufacturer’s protocols. Briefly 100ng of single-stranded cDNA
was combined to TaqMan Universal PCR Master Mix 2X
(Applied Biosystem) and water was added to a final volume of
100 ml per port. Thermal cycling conditions were the following:
50uC for 2 min, 95uC for 10 min, 40 cycles at 95uC for 15sec and
60uC for 1min. The expression level of each target gene was
normalized on GAPDH and the analysis was carried out using the
DCt method.
Detection of soluble cytokines and chemokines in cell
supernatants
After 5 hours of incubation with GDNF and GFRa1, cell
supernatants were harvested, filtered using Costar Spin-X
centrifuge tube 0.22 mm filters (Corning BV, Amsterdam, The
Netherlands) and stocked at 2800C. All tested human proteins:
CCL2, CCL3, CCL7, CCL20, CXCL1, IL-1b, CCL4, TNF, IL-6
and IL-8 were detected using commercially available R&D Duoset
sandwich ELISA development systems according to the manufac-
ture’s instructions (R&D).
Prediction analysis of the effects of RET mutations
The impact of amino acid changes detected in HSCR patients on
the structure and function of the RET protein was predicted using
the softwares like PolyPhen (Polymorphism Phenotyping; http://
genetics.bwh.harvard.edu/pph/)[41], SIFT (Sorting Intolerant
From Tolerant; http://sift.jcvi.org/www/SIFT_dbSNP.html)[42]
and Panther (http://www.pantherdb.org)[43,44]. ESEfinder v3.0
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.
cgi?process = home) was used to investigate whether the nucleotide
changes disrupted/created exonic splicing enhancers (ESEs) and/or
branch or splice sites[45]. NNSPLICE V0.9 (http://www.fruitfly.
org/seq_tools/splice.html) was also used to analyze intronic
variants[46]. Default thresholds were adopted for all the softwares.
In addition, literature data already available on functional assays
performed on some of these mutations were also used to implement
our prediction on RET mutations effects[8]. We then grouped all
variants as pathogenic mutations or mild mutations.
Statistical Analysis
RET MFIs values obtained by flow cytometry were analyzed by
performing a non parametric Kruskal Wallis test to compare the
levels of RET protein expressed on immune cell subsets.
Correlations between the amounts of the RET receptor and the
levels of RET mRNA in specific cell lines (MTC-TT, SK-N-MC,
THP1 and IMR32) were performed by using the Spearman rank
test, while differences in the amounts of RET expression among
the different genotypes were tested by the non parametric Kruskal
Wallis test. Levels of RET protein have been compared between
patients carrying pathogenic RET mutations and patients with a
wild type RET genotype by performing the non parametric
Mann-Whitney test.
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Finally, differences in gene expression levels between HSCR
patients and healthy donors, as assessed by the inflammatory
CARD (TLDA), were analyzed using the ANOVA tests for
repeated measures implemented in SPSS 17.1 (SPSS, Chicago, IL,
USA). To further validate our analyses on the identified and
candidate genes within the cohorts of 3 healthy donors and HSCR
patients, non parametric tests were performed for those compar-
isons we found significant, namely 1) the Mann-Whitney test
allowed to compare the six HSCR with the six controls for those
genes found differently expressed in the two groups irrespectively
of the treatment, 2) the Wilcoxon test was applied to the six
samples treated toward the same sample at basal expression for
those genes that were differently expressed following the treatment
and not showing differences between cases and controls, and 3) the
Mann-Whitney test allowed to assess differences of expression
before and after GDNF treatment for those genes that were
suspected to behave differently at the treatment in cases and in
controls. We set the level of significance at p = 0.05.
Gene fold increases shown in Figure 5 are represented with 2-
ddCt values, while raw data are included in Tables S3 and S4 are
indicated as dCt values. This latter set of data have been then
transformed in 2-ddCt (fold increase) by subtracting dCt of
untreated PBMCs from dCt of treated PBMCs, thus obtaining the
2-ddCt values shown in Figure 5
Supporting Information
Figure S1 Confocal microscopy of RET receptor ex-
pressed on primary immune cells. Representative examples
from an healthy donor of fluorescent confocal microscopic images
showing the expression of RET receptor on total PBMCs (panel A
with RET labeled in green and cell nucleus in blue), NK cells
(panel B with RET labeled in red, CD56 labeled in green and cell
nucleus in blue), B cells (panel C with RET labeled in red, CD19
labeled in green and cell nucleus in blue), T cells (panel D with
RET labeled in green, CD3 labeled in red and cell nucleus in
blue). The co-localization of RET with the different markers of
immune cells is labeled in yellow.
(TIF)
Figure S2 Expression of RET on lymphocyte subsets
associated with a single nucleotide polymorphism at
exon 2. Summary graph of statistical dot plots showing MFI
values of RET receptor expressed on T (left), B (center) and NK
(right) lymphocytes from 50 HSCR stratified on the basis of the
genotype at the exon 2 of RET gene (SNP rs1800858). We did not
detect any statistically significant association between the pheno-
typic distribution of RET receptor on immune cells with RET
genotype at exon 2 SNP.
(TIF)
Figure S3 Expression of RET on lymphocytes and
monocytes associated with a single nucleotide polymor-
phism at exons 11,13 and 14. Summary graph of statistical
dot plots showing MFI values of RET receptor expressed on
lymphocytes (left side of each panel) and monocytes (right side of
each panel) from 50 HSCR stratified on the basis of the genotype
at the exons 11 (left), 13 (center) and 14 (right) SNPs of RET gene.
We did not detect any statistically significant association between
the phenotypic distribution of RET receptor on immune cells with
RET genotype at exons 11,13 and 14 SNPs.
(TIF)
Figure S4 Expression of RET receptor on immune cells
from HSCR patients associated with pathogenic and not
pathogenic mutations of RET gene. Summary graph of
statistical histogram bars (upper panel) and dot plots (lower panel)
showing MFI values of RET expressed on monocytes, T, B and
NK lymphocytes from 50 HSCR patients stratified on the basis of
individuals carrying pathogenic (gray histogram bars in upper
panel and black symbols in the lower panel) or not pathogenic
RET mutation (black histogram bars in upper panel and red
symbols in the lower panel) or not carrying (empty histogram bars
in upper panel and empty symbols in the lower panel) RET
mutation at all.
(TIF)
Table S1 Prediction of RET mutation effects.
(DOCX)
Table S2 List of genes analyzed within the customized Taqman
Low Density Array (TLDA) Card.
(DOCX)
Table S3 Analysis and statistical summary of all genes included
in the customized Taqman Low Density Array Card.
(DOCX)
Table S4 Analysis and statistical summary of the 13 RET-
dependent genes whose transcripts have been measured by real
time qPCR to validate the results obtained by TLDA array.
(DOC)
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